Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IceCure Medical (ICCM) EBITDA (2020 - 2025)

Historic EBITDA for IceCure Medical (ICCM) over the last 6 years, with Q3 2025 value amounting to $3.9 million.

  • IceCure Medical's EBITDA fell 698.96% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.3 million, marking a year-over-year increase of 1052.48%. This contributed to the annual value of $15.3 million for FY2024, which is 454.55% up from last year.
  • IceCure Medical's EBITDA amounted to $3.9 million in Q3 2025, which was down 698.96% from $3.4 million recorded in Q2 2025.
  • In the past 5 years, IceCure Medical's EBITDA ranged from a high of $4.5 million in Q2 2022 and a low of $1.4 million during Q1 2021
  • For the 5-year period, IceCure Medical's EBITDA averaged around $3.6 million, with its median value being $3.8 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 22436.18% in 2022, then tumbled by 2421.56% in 2023.
  • Quarter analysis of 5 years shows IceCure Medical's EBITDA stood at $3.2 million in 2021, then increased by 25.06% to $4.0 million in 2022, then dropped by 24.22% to $3.0 million in 2023, then skyrocketed by 49.55% to $4.5 million in 2024, then dropped by 13.84% to $3.9 million in 2025.
  • Its last three reported values are $3.9 million in Q3 2025, $3.4 million for Q2 2025, and $3.6 million during Q1 2025.